Evidence map›Paper›PMID 19760660›Full record

ReviewMedicinal research reviews2011

Cellular and molecular actions of Methylene Blue in the nervous system.

Murat Oz, Dietrich E Lorke, Mohammed Hasan, George A Petroianu

Registry-linked trialAbstract readReview
In one paragraph

Review in Medicinal research reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04619290 (Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04619290 phase1unknown statusnot on this mapstarted 2020, after this paper: background citation

Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic

TypeinterventionalSponsorHospital Reg. Lic. Adolfo Lopez MateosRan2020 to 2020Enrolled46ConditionsSars Cov 2ArmsSublingual Methylene blue, Control patients
3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 427 citations in OpenAlex.

  1. Pooled it
  2. Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Murat OzIntegrative Neuroscience Section, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, Maryland 21224, USA. moz@intra.nida.nih.gov
Dietrich E Lorke
Mohammed Hasan
George A Petroianu
United Arab Emirates University · AENational Institute on Drug Abuse · US

Funding

DISCOVERY OF NOVEL MOLECULAR TARGETS FOR ENDOGENOUS AND SYNTHETIC CANNABINOIDSZ01DA000512 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHIPPENBERG, TONI · 2007 to 2008
$189k
Intramural NIH HHS NIH0011080950Intramural NIH HHS Z01 DA000512
6 · The paper itself

Abstract

Methylene Blue (MB), following its introduction to biology in the 19th century by Ehrlich, has found uses in various areas of medicine and biology. At present, MB is the first line of treatment in methemoglobinemias, is used frequently in the treatment of ifosfamide-induced encephalopathy, and is routinely employed as a diagnostic tool in surgical procedures. Furthermore, recent studies suggest that MB has beneficial effects in Alzheimer's disease and memory improvement. Although the modulation of the cGMP pathway is considered the most significant effect of MB, mediating its pharmacological actions, recent studies indicate that it has multiple cellular and molecular targets. In the majority of cases, biological effects and clinical applications of MB are dictated by its unique physicochemical properties including its planar structure, redox chemistry, ionic charges, and light spectrum characteristics. In this review article, these physicochemical features and the actions of MB on multiple cellular and molecular targets are discussed with regard to their relevance to the nervous system.

Indexed as

Alzheimer DiseaseAnimalsHumansIfosfamideMethemoglobinemiaMethylene BlueNeuronsIfosfamideMethylene Blue

Identifiers

PMID19760660
PMCPMC3005530
OpenAlexW2081058092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.